Research institute QV Bioelectronics granted £1.26 million to progress investigations into a novel approach for brain cancer treatment
QV Bioelectronics, a UK-based biotech company, is making strides in the fight against brain cancer with its innovative technology, Electric Field Therapy (EFT). The company's flagship product, the GRACE implantable system, is designed to deliver continuous, targeted therapy within the brain.
Recent preclinical studies have demonstrated strong efficacy with QV Bioelectronics' technology, according to the company. The Biomedical Catalyst funding of 1.26 million GBP awarded to QV Bioelectronics will support device validation, further safety testing, engagement with regulatory bodies, and preparations for an initial human study.
Professor of Clinical and Experimental Neurosurgery at the University of Edinburgh has stated that Electric Field Therapy has the potential to significantly improve patient outcomes and quality of life. This sentiment is echoed by the CEO of QV Bioelectronics, Dr Christopher Bullock, who called the grant a strong vote of confidence in their technology from the Innovate UK program.
Current treatments for brain cancer have limited effectiveness and poor outcomes, with glioblastoma having one of the poorest prognoses in oncology. QV Bioelectronics aims to establish GRACE as a future first-line treatment for glioblastoma, with future potential in paediatric and metastatic brain tumours.
One of the key advantages of GRACE is its ability to target tumour cells while sparing healthy tissue. This is achieved through the use of electric fields to disrupt cancer cell division, making it a promising new approach to treating glioblastoma, a particularly aggressive brain cancer.
The University of Edinburgh and NHS Lothian have contributed to the development of GRACE, and the University of Edinburgh is excited about the prospect of the first in human study for GRACE. QV Bioelectronics holds multiple granted patents and has secured over 6 million GBP in grant funding alongside equity investment.
While there are no available search results providing recent information about QV Bioelectronics' EFT device for brain tumors or its implantable system GRACE, the company has reported 'encouraging' preclinical safety and efficacy data. As of mid-2025, there is no publicly confirmed update or detailed progress report about QV Bioelectronics’ EFT device or the GRACE implantable system for brain tumors. It may be necessary to consult the company’s official communications, recent press releases, or specialized medical device market intelligence reports directly for the latest development.
Despite the lack of publicly available information, QV Bioelectronics' work on GRACE represents a significant step forward in the fight against brain cancer, offering hope for improved patient outcomes and a potential first-line treatment for glioblastoma.
The innovative technology developed by QV Bioelectronics, Electric Field Therapy (EFT), holds the potential to significantly improve patient outcomes and quality of life, particularly for those with brain cancer like glioblastoma. With the Biomedical Catalyst funding, QV Bioelectronics aims to establish GRACE, their implantable system, as a future first-line treatment for glioblastoma, addressing the limited effectiveness and poor outcomes of current medical-conditions like cancer.
